Sign In
Buy VCEL
$34.74
+0.290 (+0.84%)
At Close: Jun 03, 2026
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
08:30am, Wednesday, 03'rd Jan 2024
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co
3 Biotech Stocks That Could Boom or Bust by 2025
05:35pm, Thursday, 16'th Nov 2023
InvestorPlace published an article last December about the seven hottest biotech stocks to own in 2023 and beyond. One of the seven was the SPDR S&P Biotech ETF (NYSEARCA: XBI ).
3 Strong Buy Stocks Set to Take Off in the Coming Months
09:52pm, Friday, 10'th Nov 2023
Some of the most followed information in the stock market besides earnings releases are analyst recommendations. These are expert analyses that cover various companies that have a high potential for r
Vericel Corporation (VCEL) Q3 2023 Earnings Call Transcript
02:43pm, Wednesday, 08'th Nov 2023
Vericel Corporation (NASDAQ:VCEL ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Eric Burns - Vice President, Finance and Investor Relations Nick Colangelo - Presid
Vericel to Present at the Stephens Annual Investment Conference
08:30am, Tuesday, 07'th Nov 2023
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
08:30am, Wednesday, 25'th Oct 2023
CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will
Top Medical Stocks to Buy Amid Recent Market Volatility
07:33pm, Monday, 23'rd Oct 2023
Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare i
New Strong Buy Stocks for October 23rd
08:16am, Monday, 23'rd Oct 2023
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
New Strong Buy Stocks for October 19th
08:16am, Thursday, 19'th Oct 2023
INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.
Vericel to Present at the Morgan Stanley Global Healthcare Conference
08:30am, Wednesday, 06'th Sep 2023
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick C
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
08:30am, Thursday, 20'th Jul 2023
CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will
Vericel: Multiyear Growth Catalysts, Proprietary Solutions Will Drive Market Cap Expansion
10:57pm, Tuesday, 27'th Jun 2023
Vericel Corporation demonstrates consistent growth in its core product lines, including MACI for cartilage repair and Epicel for severe burn treatment, with significant competitive advantages and barr
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
10:41am, Wednesday, 10'th May 2023
Vericel Corporation (VCEL) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.15 per share a year ago.
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
08:30am, Wednesday, 26'th Apr 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it wil
Vericel Corporation: A Promising Future In Advanced Cell Therapies
09:14am, Sunday, 02'nd Apr 2023
The FDA's recent approval of NexoBrid for the treatment of burns is expected to drive revenue growth in 2023. Vericel's MACI autologous cell therapy product for knee cartilage defects is on track for
